Thermo Fisher Scientific, the world leader in serving science, and QIAGEN, a Germany-based pharmaceutical company, have agreed to combine their businesses and create a leading global biotechnology company.
This was the first German/US public offer ever made for a Dutch NV company. As lead counsel to QIAGEN, we led an international team of lawyers advising QIAGEN on this multi-billion cross-border transaction.
Read more about this deal here.
De Brauw team: Arne Grimme, Martin van Olffen, Bernard Spoor, Casper Nagtegaal, Frank Hamming, Eveline de Waard, Ioana Patrascu, Matthijs Verwer, Maarten van der Weijden, Klaas Versteeg and Pim Siemons.
De Brauw Blackstone Westbroek
Claude Debussylaan 80
1082 MD Amsterdam
The Netherlands
P.O. Box 75084
1070 AB Amsterdam
The Netherlands
